Company intelligence / Profile preview
Eucure Biopharma
Beijing, Beijing, Chinaeucure.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has multiple products in clinical trials, with two products in Phase 2 multi-regional clinical trials (MRCTs) and two in Phase 1 clinical trials. YH001 (anti-CTLA-4) and YH003 (anti-CD40) have shown promising results in Phase 1 trials and have been approved for Phase 2 trials by the FDA.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
TRACON PharmaceuticalsISU ABXISSyncromuneJunshi Biosciences
Beyond the preview
Go deeper on Eucure Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eucure Biopharma.